Peregrine shares spike on Ph2 cancer data

Shares of Peregrine Pharmaceuticals ($PPHM) spiked 20% this morning after the company reported that advanced and metastatic breast cancer patients taking a combination of bavituximab and docetaxel experienced a median survival rate of 20.7 months in a prior single arm Phase II study involving 46 patients. Release